These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 36279982)
1. Drug conjugate-based anticancer therapy - Current status and perspectives. Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982 [TBL] [Abstract][Full Text] [Related]
2. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions. Li C; Shi K; Zhao S; Liu J; Zhai Q; Hou X; Xu J; Wang X; Liu J; Wu X; Fan W Pharmacol Res; 2024 Sep; 207():107341. PubMed ID: 39134188 [TBL] [Abstract][Full Text] [Related]
3. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs? Zhang B; Wang M; Sun L; Liu J; Yin L; Xia M; Zhang L; Liu X; Cheng Y J Med Chem; 2024 Jul; 67(14):11469-11487. PubMed ID: 38980167 [TBL] [Abstract][Full Text] [Related]
4. Peptide Drug Conjugates and Their Role in Cancer Therapy. Heh E; Allen J; Ramirez F; Lovasz D; Fernandez L; Hogg T; Riva H; Holland N; Chacon J Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614268 [TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209 [TBL] [Abstract][Full Text] [Related]
6. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Lindberg J; Nilvebrant J; Nygren PÅ; Lehmann F Molecules; 2021 Oct; 26(19):. PubMed ID: 34641586 [TBL] [Abstract][Full Text] [Related]
10. Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Xu J; Li X; Du Y Adv Biol (Weinh); 2022 Mar; 6(3):e2101065. PubMed ID: 35122418 [TBL] [Abstract][Full Text] [Related]
11. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment. Pramanik D Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237 [TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update. Dias E Silva D; Andriatte GM; Pestana RC Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909 [TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates for Cancer Therapy. Hafeez U; Parakh S; Gan HK; Scott AM Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383 [TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates: Principles and opportunities. Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384 [TBL] [Abstract][Full Text] [Related]
16. Stepping forward in antibody-drug conjugate development. Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334 [TBL] [Abstract][Full Text] [Related]
17. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. Alas M; Saghaeidehkordi A; Kaur K J Med Chem; 2021 Jan; 64(1):216-232. PubMed ID: 33382619 [TBL] [Abstract][Full Text] [Related]
18. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Ferraro E; Drago JZ; Modi S Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530 [TBL] [Abstract][Full Text] [Related]
19. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Tong JTW; Harris PWR; Brimble MA; Kavianinia I Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391 [TBL] [Abstract][Full Text] [Related]
20. Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells. Porębska N; Ciura K; Chorążewska A; Zakrzewska M; Otlewski J; Opaliński Ł Biotechnol Adv; 2023 Oct; 67():108213. PubMed ID: 37453463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]